Optic pathway glioma: lines of therapy

Cancer page →

2 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers
Second line	1
Other settings	1

Second line

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Threatened vision or progression	Carboplatin and vincristine, or selumetinib (phase 2, Fangusaro 2019), tovorafenib, or dabrafenib with trametinib for BRAF V600E; radiotherapy deferred.	CarboplatinVincristineSelumetinibTovorafenibDabrafenibTrametinib		86

Other settings

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Stable vision	Observation with ophthalmology and MRI follow-up.	Paediatric low-grade glioma		-

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.